G. Kristensen

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
G. Balle Kristensen, G. B. Kristensen, G.b. Kristensen, G Kristensen, Gunnar B Kristensen, Gunnar B. Kristensen, Gunnar Balle Kristensen, G B Kristensen, Gunnar Kristensen, G. Kristensen
Publication record
314 papers · 22,542 citations · H-index 71

PAPERS

CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data
202315 citationsauthor #6
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
202313 citationsauthor #25
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
202317 citationsauthor #172
Pelvic exenteration for vulvar cancer: Postoperative morbidity and oncologic outcome - A single center retrospective analysis.
20239 citationsauthor #4
miR‐200a/b/‐429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer
202211 citationsauthor #9
Risk of recurrence after chemoradiotherapy identified by multimodal MRI and 18F-FDG-PET/CT in locally advanced cervical cancer.
202210 citationsauthor #6
OC-0596 Gene regulatory networks of metabolic stress responses in cervical cancer
20220 citationsauthor #11
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial
202226 citationsauthor #3
OC-0280 Tumour hypoxia and immunity as predictors of chemoradiotherapy outcome in cervical cancer
20210 citationsauthor #4
Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification
202177 citationsauthor #6
Salvage Radiation for Pelvic Relapse after Surgically Treated Endometrial Cancer
202111 citationsauthor #7
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.
2021231 citationsauthor #18
Long-term oncological outcomes and recurrence patterns in early-stage cervical cancer treated with minimally invasive versus abdominal radical hysterectomy: The Norwegian Radium Hospital experience.
202120 citationsauthor #2
OC-0403 MiR-200 family members as predictive biomarkers for radioresistance in cervical cancer
20210 citationsauthor #8
Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care
202033 citationsauthor #14
Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer
202057 citationsauthor #7
DCE-MRI of locally-advanced carcinoma of the uterine cervix: Tofts analysis versus non-model-based analyses
20200 citationsauthor #3
DCE-MRI of locally-advanced carcinoma of the uterine cervix: Tofts analysis versus non-model-based analyses
20209 citationsauthor #3
MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
2020115 citationsauthor #27
MRI Distinguishes Tumor Hypoxia Levels of Different Prognostic and Biological Significance in Cervical Cancer
202037 citationsauthor #10
Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity
202023 citationsauthor #6
MR Imaging Distinguishes Tumor Hypoxia Levels of Different Prognostic and Biological Significance in Cervical Cancer
20200 citationsauthor #10
Prognostic Value of the Diversity of Nuclear Chromatin Compartments in Gynaecological Carcinomas
20200 citationsauthor #4
Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes
201916 citationsauthor #15
Pharmacokinetic analysis of DCE-MRI data of locally advanced cervical carcinoma with the Brix model
201910 citationsauthor #3
Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer
201949 citationsauthor #7
Mitochondrial Function of CKS2 Oncoprotein Links Oxidative Phosphorylation with Cell Division in Chemoradioresistant Cervical Cancer
201922 citationsauthor #5
Reference MicroRNAs for RT-qPCR Assays in Cervical Cancer Patients and Their Application to Studies of HPV16 and Hypoxia Biomarkers
201918 citationsauthor #4
Progression free survival (PFS) as a surrogate endpoint for overall survival (OS) in first-line advanced ovarian cancer (AOC) therapy: A Gynecologic Cancer InterGroup individual (GCIG) patient-level (IPD) analysis of multiple randomized trials.
20180 citationsauthor #7
Association Between Proportion of Nuclei With High Chromatin Entropy and Prognosis in Gynecological Cancers
20185 citationsauthor #7
DCE-MRI-Derived Measures of Tumor Hypoxia and Interstitial Fluid Pressure Predict Outcomes in Cervical Carcinoma.
201817 citationsauthor #4
OP-JNCI180073 1400..1408
20180 citationsauthor #7
Progression free survival as a surrogate endpoint for overall survival in first-line therapy of advanced ovarian cancer: A Gynecologic Cancer InterGroup (GCIG) individual patient-level meta-analysis
20180 citationsauthor #7
VERSUS UPFRONT DEBULKING SURGERY IN ADVANCED TUBO-OVARIAN
20180 citationsauthor #4
Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only
20189 citationsauthor #5
Chromatin organisation and cancer prognosis: a pan-cancer study
201872 citationsauthor #8
1540OFosaprepitant reduces the impact of nausea on daily function during five weeks of chemo-radiotherapy: A sub-study of the GAND-emesis trial
20171 citationsauthor #8
Combination chemotherapy with nintedanib/placebo for patients with advanced or recurrent endometrial cancer: The NSGO ENGOT-EN1/FANDANGO trial.
20173 citationsauthor #10
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
201728 citationsauthor #13
Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting.
201728 citationsauthor #7
Pretreatment late-phase DCE-MRI predicts outcome in locally advanced cervix cancer
20177 citationsauthor #3
Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
201743 citationsauthor #15
Vulvar carcinoma in Norway: A 50-year perspective on trends in incidence, treatment and survival.
201752 citationsauthor #3
A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway
201731 citationsauthor #12
961P ICON7: ovarian cancer, platinum second-line chemotherapy and overall survival.
20174 citationsauthor #5
Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab
201628 citationsauthor #9
Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.
201636 citationsauthor #9
Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma.
201646 citationsauthor #5
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.
2016210 citationsauthor #6
Identification and Validation of Reference Genes for RT-qPCR Studies of Hypoxia in Squamous Cervical Cancer Patients
201632 citationsauthor #4
L1CAM as a prognostic marker in stage I endometrial cancer: a validation study
201635 citationsauthor #7
Meta-analysis of the randomized EORTC and chorus neoadjuvant versus primary debulking trials in advanced tubo-ovarian cancer.
20162 citationsauthor #4
L1CAM as a prognostic marker in stage I endometrial cancer: a validation study
20160 citationsauthor #7
Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer
201650 citationsauthor #7
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
2016200 citationsauthor #2
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
201642 citationsauthor #2
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
201630 citationsauthor #6
Prognostic and predictive value of primary vs secondary platinum resistance for bevacizumab treatment in platinum-resistant ovarian cancer in the AURELIA trial.
20151 citationsauthor #6
Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer
201554 citationsauthor #7
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
2015778 citationsauthor #7
2748 Assessment of associations between disease stage and toxicity with bevacizumab (BEV) in ICON7, a phase III trial of front-line carboplatin/paclitaxel (CP) ± BEV for ovarian cancer (OC)
20151 citationsauthor #8
34LBA Fosaprepitant for the prevention of nausea and emesis during five weeks of chemo-radiotherapy: A multinational randomised, placebo-controlled, double-blind trial – the GAND-emesis study
20150 citationsauthor #8
Short-term pretreatment DCE-MRI in prediction of outcome in locally advanced cervical cancer.
201526 citationsauthor #4
2703 Computed tomography is more sensitive than CA 125 in detecting disease progression in patients with platinum-resistant ovarian cancer: Analysis of the AURELIA trial
20150 citationsauthor #2
Exploratory outcome analyses according to stage and residual disease in the ICON7 trial of front-line carboplatin/paclitaxel (CP) ± bevacizumab (BEV) for ovarian cancer (OC).
20156 citationsauthor #7
Multinational study exploring patients' perceptions of side-effects induced by chemo-radiotherapy.
201535 citationsauthor #5
ASSOCIATIONS BETWEEN DISEASE STAGE AND TOXICITY WITH BEVACIZUMAB (BEV) IN ICON7, A PHASE III TRIAL OF FRONT-LINE CARBOPLATIN/PACLITAXEL (CP) plus /- BEV FOR OVARIAN CANCER (OC)
20150 citationsauthor #8
Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients.
201513 citationsauthor #8
19th International Meeting of the European Society of Gynecological Oncology (ESGO 2015)
20154 citationsauthor #2
Peritumoral interstitial fluid flow velocity predicts survival in cervical carcinoma.
201429 citationsauthor #4
PO-0963: Mitochondrial function of the prognostic cell cycle regulatory gene CKS2 in cervical cancer
20140 citationsauthor #4
Entropy-Based Adaptive Nuclear Texture Features are Independent Prognostic Markers in a Total Population of Uterine Sarcomas
201416 citationsauthor #5
A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer
20146 citationsauthor #8
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine Serous Carcinoma
201453 citationsauthor #10
PD-0431: HIF1 signaling in aggressive hypoxic cervical tumors
20140 citationsauthor #4
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
20141,433 citationsauthor #6
A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer
20140 citationsauthor #8
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Mullerian Adenosarcoma of the Female Genital Tract
201453 citationsauthor #5
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Endometrial Stromal Sarcoma
201485 citationsauthor #4
Identification of a Genomic Signature Predicting for Recurrence in Early Stage Ovarian Cancer
20140 citationsauthor #3
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
201438 citationsauthor #5
Gene expression signatures of primary and metastatic uterine leiomyosarcoma.
201482 citationsauthor #8
Independent review of AGO-OVAR 12, a GCIG/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC).
20148 citationsauthor #1
Identification of eight candidate target genes of the recurrent 3p12–p14 loss in cervical cancer by integrative genomic profiling
201349 citationsauthor #11
Abstract 401: Gene expression signatures differentiate primary and metastatic uterine leiomyosarcoma.
20130 citationsauthor #6
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial
2013149 citationsauthor #4
Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy.
201362 citationsauthor #2
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer.
201340 citationsauthor #18
Abstract 4037: HIF1α signaling contributes to an aggressive hypoxic phenotype in cervical cancer.
20131 citationsauthor #4
High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival
201327 citationsauthor #14
Reliability of core needle biopsy for determining ER and HER 2 status in breast cancer
20134 citationsauthor #13
Abstract 807: Eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer.
20130 citationsauthor #4
Long-term outcomes after pelvic radiation for early-stage endometrial cancer.
201379 citationsauthor #5
Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
201230 citationsauthor #13
Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome.
201280 citationsauthor #5
The European Network of Gynecological Oncological Trial Groups
20120 citationsauthor #4
Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI.
2012137 citationsauthor #9
Genomic imbalances in endometrial adenocarcinomas — Comparison of DNA ploidy, karyotyping and comparative genomic hybridization
20128 citationsauthor #5
O521 SURVIVAL AFTER POSTOPERATIVE RADIOTHERAPY FOR EARLY STAGE ENDOMETRIAL CARCINOMA: THE OSLO STUDY REVISITED AFTER UP TO 43 YEARS OF FOLLOW‐UP
20121 citationsauthor #3
Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium.
20126 citationsauthor #6

TIMELINE

1980 2 citations

1981 0 citations

1983 3 citations

1984 34 citations

1985 11 citations

1988 29 citations

1989 33 citations

1990 23 citations

1991 91 citations

1992 217 citations

1993 269 citations

1994 92 citations

1995 469 citations

1996 511 citations

1997 384 citations

1998 315 citations

1999 522 citations

2000 778 citations

2001 428 citations

2002 49 citations

2003 1,690 citations

2004 795 citations

2005 1,153 citations

2006 409 citations

2007 239 citations

2008 330 citations

2009 651 citations

2010 4,656 citations

2011 2,714 citations

2012 702 citations

2013 411 citations

2014 1,803 citations

2015 918 citations

2016 711 citations

2017 197 citations

2018 103 citations

2019 115 citations

2020 274 citations

2021 339 citations

2022 47 citations

2023 54 citations

G. Kristensen

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT